Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 Alone or With Chemotherapy in Resectable NSCLC
NCT05247684Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2022
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Feb 2022; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05247684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247684.